Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
SIESTA - Home sleep study with BresoDx for obstructive sleep apnea: a randomized controlled trial
Sleep Medicine, Volume 65, Year 2020
Notification
URL copied to clipboard!
Description
Study objectives: The objectives of this study were to evaluate (1) the accuracy of the clinical diagnosis of obstructive sleep apnea (OSA) informed by the home sleep study with a Type 4 portable monitor BresoDx® versus Type 1 polysomnography (PSG); and (2) agreement of the apnea-hypopnea index (AHI) compared between BresoDx and PSG. Material and methods: This was a randomized, parallel, multicentre, single-blind, pragmatic controlled trial enrolling adults referred to three Ontario sleep clinics for suspected OSA. Participants were randomized to BresoDx followed by PSG (one-night apart) or PSG followed by BresoDx sleep testing sequence arms. The primary outcomes included the accuracy of clinical diagnosis and OSA severity measured by AHI between tests. Results: In sum, 233 participants completed both sleep studies and 206 completed physician consultation visits. The agreement between clinical diagnosis informed by PSG versus BresoDx was fair (Cohen's kappa coefficient = 0.28). The sensitivity of BresoDx-informed clinical diagnosis against PSG was between 0.86 and 0.89, and the specificity between 0.38 and 0.44. For AHI cut-off of ≥5 events/hour the sensitivity, specificity and positive and negative predictive values were 0.85, 0.48, 0.81 and 0.54. Conclusions: Home sleep apnea testing with BresoDx can be used in a referral population with a high pretest probability of OSA similar to other Type IV devices. This study complements the existing body of evidence suggesting that home testing with portable devices plays a valuable role for diagnosing of OSA in a variety of settings. SIESTA trial registration: www.clinicaltrials.gov (Identifier: NCT02003729). © 2019 Elsevier B.V.
Authors & Co-Authors
Fitzpatrick, Michael F.
Canada, Kingston
Queen’s University
Rac, Valeria E.
Canada, Toronto
Toronto General Hospital
Canada, Toronto
Toronto Health Economics and Technology Assessment Collaborative University of Toronto
Canada, Toronto
University of Toronto
Pechlivanoglou, Petros
Canada, Toronto
University of Toronto
Canada, Toronto
Sickkids Research Institute
Pham, Ba’ Z.
Canada, Toronto
Toronto Health Economics and Technology Assessment Collaborative University of Toronto
Zwarenstein, Merrick F.
Canada, London
Western University
Krahn, Murray D.
Canada, Toronto
Toronto Health Economics and Technology Assessment Collaborative University of Toronto
Canada, Toronto
University of Toronto
Statistics
Citations: 6
Authors: 6
Affiliations: 8
Identifiers
Doi:
10.1016/j.sleep.2019.07.013
ISSN:
13899457
Research Areas
Disability
Study Design
Cross Sectional Study
Study Approach
Quantitative